Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Technology Update

5 Jan 2007 07:53

ViaLogy PLC05 January 2007 Date: 5 January 2007On behalf of: ViaLogy plc ("ViaLogy" or "the Company")Embargoed until: 0700hrs ViaLogy plc Technology Update ViaLogy achieves significant improvement in $5 billion MEMS technology growtharea LONDON, January 5, 2007 -- ViaLogy plc (AIM: VIY), is pleased to announced thata major improvement in the performance of a vital piece of equipment used in theaerospace and military industries has been achieved in a collaboration betweenViaLogy, Boeing and NASA's Jet Propulsion Laboratory (JPL) in Pasadena, CA. Scientists at ViaLogy, a leading innovator of real-time network-centric signalprocessing platforms for sensor applications in defense, aerospace, homelandsecurity and the life sciences, have achieved a 10X improvement in the stabilityand performance of the JPL/Boeing miniature vibratory gyroscope. Gyros are an integral part of all space control systems, determining thealtitude and rotational rates for navigation. They are used to sense and measurerotational motion, often in harsh environments, and must be sufficiently robustto reliably deliver real time information continuously for several years. Forspace applications, gyros are made using microelectromechanical systems (MEMS)sensors which combine electrical and mechanical components on the same siliconsubstrate. The design of the miniature device allows for a smaller, lighter andmore durable low power system. ViaLogy CEO Michael Kelly explains: "We have developed proprietary signalprocessing software to short-circuit complex device engineering and deliver MEMSsensors which are on a par with the performance of much bulkier and entrenchedversions. Costs are also greatly reduced." The development work has been tested on the JPL/Boeing miniature vibratorygyroscope. Dr Karl Yee, JPL manager on the project, comments: "Vialogy'sembedded multi-scale estimator shows a significant real-time improvement ofsensor performance. We were able to observe at first hand a 10X improvementusing data from our Post Resonator Gyroscope. Indications are that MEMS gyroperformance can now match that of traditional ring laser and fiber opticgyroscopes. This offers exciting prospects for MEMS in general and I believe thesolution can rapidly scale to numerous military and civilian space applications." The successful development of the gyro enhancement software opens up animportant new market for ViaLogy. The same approach is broadly applicable toother MEMS sensors, including accelerometers, clock, GPS and resonator devices.MEMS is one of the fastest growing technology areas, with annual sales of around$5 billion and growing at a rate of approximately 20% per annum. The MEMS gyromarket alone is expected to reach around $800 million by 2010. The growth alsocomes from high-volume commodity applications in automotive, medical, commercialand consumer products. Global commercial players include Honeywell, Switech,Bosch, Analog Devices, HGS IMIT, THALES and Panasonic. One of the constraints on expansion of MEMS inertial sensors has been biasdrift, gain fluctuation and mechanical variation. ViaLogy has developed a novelactive error suppression technique, for which it has a patent pending. ViaLogy's Director of Product Development, Dr. Tom George, who previously headedthe MEMS technology group at NASA/JPL, says: "We are delighted with the successof the work we have done with JPL and Boeing. We have achieved a milestone thathas broad implications. The need for frequent resetting of the self-calibratingMEMS sensors will be greatly reduced and their performance will be consistentthroughout their design lifetime. Also, our gyro enhancement solution footprintis compact and designed to be included in silicon modules that can be easilyincorporated within the existing manufacturing processes used in commercial MEMSfoundries. "We have taken the lead in applying computational technologies to overcome thesignal-to-noise challenge in MEMS." For further information please contact: ViaLogyMichael Kelly, CEO - US +1 626 296 6337Terry Bond, Chairman - UK & Europe +44 (0)20 7869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defense andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.